Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(6):427–432. doi: 10.1002/clc.4960230610

Response to changing plasma concentrations of isosorbide‐bound no2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease

Lars H Jørgensen 1,✉, Erik Thaulow 1, Harald E Refsum 1, Jan Bredesen 2
PMCID: PMC6655186  PMID: 10875033

Abstract

Background: The mechanisms behind development of tolerance to nitrate effects during sustained, asymmetric isosorbide dinitrate (ISDN) therapy are not fully understood.

Hypothesis: The study was undertaken to investigate the changes of the relationships between left ventricular (LV) function and plasma concentrations of ISDN and its vasoactive metabolites (2‐ and 5‐ISMO) during acute and sustained, asymmetric ISDN therapy.

Methods: Left ventricular function and plasma concentrations of ISDN, 2‐ and 5‐isosorbide mononitrates (P‐ISDN, P‐2‐and 5‐ISMO) were measured at rest and at supine exercise before and for 4 h after peroral 30 mg ISDN in 15 patients with coronary artery disease, all with initial exercise pulmonary artery wedge pressure (PAWP) > 25 mmHg. Seven patients were untreated (acute group), while eight received 30 mg ISDN b.i.d. for 2 weeks before the invasive study. P‐ISDN and the concentration of available isosorbide‐bound nitrate (NO2) in plasma (P‐ISDN‐2 + P‐2‐ISMO + P‐5‐ISMO) (P‐NO2) were used as measures of the nitric oxide (NO) offer to the tissues.

Results: Throughout the study, after administration of medication, all plasma concentrations, in particular P‐ISDN, were higher in the chronic than in the acute group. Peak P‐ISDN was reached after 15 min in the chronic group and after 25 min in the acute group, while P‐2‐ and 5‐ISMO reached maximum only after 40 min in both groups. At rest, the full effect on PAWP was observed after 10 min in both groups, but at markedly higher levels of P‐ISDN and P‐NO2 in the chronic group. Afterward, no further changes in PAWP were observed. During exercise, 1 h after medication, PAWP and stroke index to PAWP ratio (SI/PAWP) were normal in both groups. Thereafter, at slowly declining P‐NO2, PAWP rose and SI/PAWP declined toward the initial level in the chronic group, but remained unchanged in the acute group, in spite of higher P‐NO2 and greater NO release in the former.

Conclusions: Patients receiving sustained, asymmetric 30 mg ISDN b.i.d. dosing had the same immediate beneficial effects on LV function during exercise after a morning dose as did untreated patients. However, in spite of higher P‐NO2 and higher rate of NO release during sustained treatment, the effects deteriorated gradually 2 to 3 h after medication. The changes in metabolism and/or distribution of isosorbide‐bound NO2 may possibly be part of the tolerance induced by long‐term treatment, even with asymmetric dosing.

Keywords: plasma concentrations of isosorbide dinitrate, 2‐and 5‐ISMO, left ventricular function

Full Text

The Full Text of this article is available as a PDF (675.4 KB).

Reference

  • 1. Thadani U, Fung HL, Darke AC, Parker JO: Oral isosorbide dinitrate in the treatment of angina pectoris. Dose‐response relationship and duration of action during acute therapy. Circulation 1980; 62: 491–502 [DOI] [PubMed] [Google Scholar]
  • 2. Reichek N, Priest C, Zimrin D, Chandler T, St John Sutton M: Antianginal effects of nitroglycerin patches. Am J Cardiol 1984; 54: 1–7 [DOI] [PubMed] [Google Scholar]
  • 3. Parker JO, Fung HL: Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984; 54: 471–476 [DOI] [PubMed] [Google Scholar]
  • 4. Parker JO, Farrell B, Lahey KA, Moe G: Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316: 1440–1444 [DOI] [PubMed] [Google Scholar]
  • 5. Naito H, Matsuda Y, Shiomi K, Yorozu T, Maeda T, Lee H, Seki K, Nakashima H: Effects of sublingual nitrate in patients receiving sustained therapy of isosorbide dinitrate for coronary artery disease. Am J Cardiol 1989; 64: 565–568 [DOI] [PubMed] [Google Scholar]
  • 6. Makhoul N, Dakak N, Flugelman MY, Merdler A, Shefer A, Schneeweiss A, Halon DA, Lewis BS: Nitrate tolerance in heart failure: Differential venous, pulmonary and systemic arterial effects. Am J Cardiol 1990; 65: 28J–31J [DOI] [PubMed] [Google Scholar]
  • 7. Ghio S, de Servi S, Perotti R, Eleuteri E, Montemartini C, Specchia G: Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Effects of N‐acetylcystein administration. Circulation 1992; 86: 798–802 [DOI] [PubMed] [Google Scholar]
  • 8. Silber S: Nitrates: Why and how should they be used today? Eur J Pharmacol 1990; 38 (suppl 1): S35–S51 [DOI] [PubMed] [Google Scholar]
  • 9. Elkayam U, Roth R, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnson JV, Rahimtoola SH: Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 1991; 84: 2040–2048 [DOI] [PubMed] [Google Scholar]
  • 10. Thadani U: Role of nitrates in angina pectoris. Am J Cardiol 1992; 70: 43B–53B [DOI] [PubMed] [Google Scholar]
  • 11. Jørgensen LH, Refsum HE, Thaulow E: Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetrical isosorbide dinitrate treatment in patients with ischemic heart disease. Clin Cardiol 1994; 17: 65–70 [DOI] [PubMed] [Google Scholar]
  • 12. Jørgensen LH, Thaulow E, Refsum HE: Hemodynamic time course of acute and chronic isosorbide dinitrate treatment at rest and during exercise in patients with stable ischemic heart disease. Clin Cardiol 1996; 19: 718–724 [DOI] [PubMed] [Google Scholar]
  • 13. Nordenfeldt J, Adolfson L, Nilsson JE, Olsson S: Reference values for exercise tests with continuous increase in load. Clin Physiol 1985: 5; 161–172 [DOI] [PubMed] [Google Scholar]
  • 14. Morrison RA, Fung HL: Determination of the partitioning, stability and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas‐liquid chromatography assay. J Chromatogr 1984; 308: 153–164 [DOI] [PubMed] [Google Scholar]
  • 15. Fung HL, Parker JO: Prolonged plasma halflife after oral isosorbide dinitrate in patients with angina pectoris. Br J Clin Pharmacol 1983; 15: 746–748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Abshagen U, Betzien G, Endele R, Kaufmann B, Neugebauer G: Pharmacokinetics and metabolism of isosorbide dinitrate after intravenous and oral administration. Eur J Clin Pharmacol 1985; 27: 637–644 [DOI] [PubMed] [Google Scholar]
  • 17. Reifart N, Bussmann W‐D, Schirmer M, Kalterbach M: Haemodynamische Wirksamkeit, Wirkdauer und Pharmakokinetik von 80 mg Isosorbid‐5‐Mononitrat beim frischen Herzinfarkt. Med Welt 1981; 32: 540–542 [PubMed] [Google Scholar]
  • 18. Abshagen UWP: Pharmacokinetics of isosorbide mononitrate. Am J Cardiol 1992; 70: 61G–66G [DOI] [PubMed] [Google Scholar]
  • 19. Shane SJ, Jazetta JJ, Chrisholm AW, Berka JF, Leung D: Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man. Br J Clin Pharmacol 1978; 6: 37–41 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Thadani U, Fung HL, Darke AC, Parker JO: Oral isosorbide dinitrate in angina pectoris. Comparison of duration of action and dose‐response relation during acute and sustained therapy. Am J Cardiol 1982; 49: 411–419 [DOI] [PubMed] [Google Scholar]
  • 21. Elkayam U: Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114: 667–677 [DOI] [PubMed] [Google Scholar]
  • 22. Fung HL, McNiff EF, Ruggirello D, Darke A, Thadani U, Parker JO: Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br J Clin Pharmacol 1981; 11: 579–590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Morrison RA, Wiegand UW, Jähnchen E, Höhmann D, Bechtold H, Meinertz T, Fung HL: Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. Clin Pharmacol Ther 1983; 33: 747–756 [DOI] [PubMed] [Google Scholar]
  • 24. Fung HL: Pharmacokinetic determinants of nitrate action. Am J Med 1984; 76: 22–26 [DOI] [PubMed] [Google Scholar]
  • 25. Schneider W, Menke G, Heidemann R, Satter P, Kaltenbach M, Rietbrock R: Concentrations of isosorbide dinitrate, isosorbide‐2‐mononitrate and isosorbide‐5‐mononitrate in human vascular and muscle tissue under steady state conditions. Eur Clin Pharmacol 1990; 38: 145–147 [DOI] [PubMed] [Google Scholar]
  • 26. Laufen H, Aumann M, Leitold M: Oral absorption and distribution of isosorbide dinitrate and mononitrates in man. Arzneim‐Forsch/Drug Res 1983; 33: 980–984 [PubMed] [Google Scholar]
  • 27. Taylor T, Chasseaud LF, Major R, Doyle E, Darragh A: Isosorbide 5‐mononitrate mononitrate pharmacokinetics in humans. Biopharm Drug Disp 1981; 2: 255–263 [DOI] [PubMed] [Google Scholar]
  • 28. Taylor T, Chasseaud LF, Doyle E, Bonn R, Darragh A, Lambe RF: Isosorbide dinitrate pharmacokinetics. Arzneim Forsch/Drug Res 1982; 32 (II): 1329–1333 [PubMed] [Google Scholar]
  • 29. Chasseaud LF, Darragh A, Doyle E, Lambe RF, Taylor T: Isosorbide dinitrate plasma concentrations in human subjects after administration of standard oral and sublingual formulations. J Pharm Sci 1984; 73: 699–701 [DOI] [PubMed] [Google Scholar]
  • 30. Straehl P, Galeazzi RL: Isosorbide bioavailability, kinetics and metabolism. Clin Pharmacol Ther 1985; 38: 140–149 [DOI] [PubMed] [Google Scholar]
  • 31. Abshagen U, Betzien G, Endele R, Kaufmann B: Pharmacokinetics of intravenous and oral isosorbide‐5‐mononitrate. Eur J Clin Pharmacol 1981; 20: 269–275 [DOI] [PubMed] [Google Scholar]
  • 32. Thadani U, Prasad R, Hamilton SF, Doyle R, Karpow S, Reder R, Teague SM: Usefulness of twice‐daily isosorbide‐5‐mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 1987; 60: 477–482 [DOI] [PubMed] [Google Scholar]
  • 33. Fung HL: Pharmacokinetics and pharmacodynamics of organic nitrates. Am J Cardiol 1987; 60: 4H–9H [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES